Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race
Chinese Firm Is Partnered With Second Place Contender Janssen In US
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
You may also be interested in...
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.
Three requests for the accelerated assessment of planned EU marketing applications were considered by the European Medicines Agency last month.
Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.